Location History:
- Taoyuan County, TW (2016 - 2018)
- Taoyuan, TW (2021 - 2023)
Company Filing History:
2 out of 117 
2 out of 125 
1 out of 1 Years Active: 2016-2023
Title: Innovations in Cancer Treatment: The Contributions of Su-Jung Chen
Introduction
Su-Jung Chen, an accomplished inventor based in Taoyuan, Taiwan, has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of six patents, Chen is at the forefront of developing targeted therapies that address critical challenges in cancer diagnosis and management.
Latest Patents
Two of Su-Jung Chen's latest patents showcase his pioneering efforts in the development of radiotherapy medications. The first patent is centered around a novel precursor designed for radioisotope labeling with ligands that specifically bind to prostate-specific membrane antigen (PSMA). This innovative method is crucial for the diagnosis and treatment of prostate cancer, allowing the use of radioactive isotopes like Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 for imaging analysis of human tumor models. By providing a pharmacophore of a PSMA inhibitor, which comprises three molecules of glutamic acid, urea, and lysine, Chen’s invention enhances the therapeutic and diagnostic capabilities for prostate cancer.
The second patent pertains to a compound targeting fibroblast activation protein, including its preparation methods and applications. This compound is represented by the formula (I) D-R1-R2-A-R' or its salt, and it demonstrates potential uses in enhancing cancer treatment approaches, thereby contributing to advances in the medical field.
Career Highlights
Throughout his career, Su-Jung Chen has been associated with prominent research institutions, including the Institute of Nuclear Energy Research and the Atomic Energy Council under the Executive Yuan, Republic of China (Taiwan). His work in these institutions has allowed him to apply his expertise in nuclear energy and radiation therapy toward developing innovative cancer treatments.
Collaborations
Chen has collaborated with esteemed colleagues, including Sheng-Nan Lo and Shih-Ying Lee, to further his research. Their collective efforts have played a significant role in advancing cancer treatment technologies, showcasing the importance of teamwork in driving innovation.
Conclusion
In summary, Su-Jung Chen stands out as a key figure in the realm of cancer innovation with his six patents reflecting groundbreaking advancements in targeted radiotherapy and compound development. His contributions continue to pave the way for improved diagnosis and treatment methods, ultimately benefiting patients suffering from prostate cancer and potentially other malignancies. Chen’s work highlights the essential relationship between innovation and healthcare, demonstrating how dedicated inventors can transform lives through their discoveries.